深圳市成人新型冠状病毒奥密克戎变异株感染重症临床救治专家共识  

Expert consensus on clinical management of severe/critical Omicron subvariant infection in adults in Shenzhen

作　　者：深圳市第三人民医院,国家感染性疾病临床医学研究中心,深圳市感染性疾病质量控制中心 卢洪洲 刘映霞[3] 黄佳 Shenzhen Third People's Hospital,National Clinical Research Center for Infectious Diseases,Shenzhen Infectious Disease Quality Control Center

机构地区：[1]不详 [2]深圳市第三人民医院/国家感染性疾病临床医学研究中心 [3]深圳市第三人民医院/国家感染性疾病临床医学研究中心,深圳市感染性疾病质量控制中心 [4]深圳市第三人民医院重症医学科

出　　处：《新发传染病电子杂志》2023年第1期93-101,共9页Electronic Journal of Emerging Infectious Diseases

基　　金：国家科技重大专项(2022YFB3207205);广东省高水平临床重点专科(感染性疾病科)项目(SZGSP011);深圳市科创委课题项目(JSGG20200207161928126)。

摘　　要：随着新型冠状病毒奥密克戎(Omicron)变异株的出现和进化分支上的多种变异株流行,全球新型冠状病毒感染(COVID-19)疫情防控形势发生了变化。我国人群目前感染的主要变异株是新型冠状病毒BA.5及其分支亚型BA.5.2和BF.7,感染后可发展为重型/危重型,甚至导致高危人群死亡。本共识基于国内外新型冠状病毒感染的流行病学、临床研究等方面数据,以及循证医学证据,聚焦新型冠状病毒Omicron变异株感染成人重型或危重型患者的临床特点、病情进展的相关指标、影像学特征、抗病毒治疗、呼吸支持治疗、抗凝及血液净化治疗、中医治疗、转出ICU标准等内容,提炼出10条共识建议。特别是对抗病毒治疗选择、疗程等提出了新的见解。The global pandemic has changed with the emergence of omicron strains and the prevalence of multiple variants on their evolutionary branches.Infection in China is currently dominated by BA.5 and its sub-lineage variants BA.5.2 and BF.7.Infection may lead to severe/critical situation,and even to death in high-risk groups.Based on the epidemiological and clinical research data of COVID-19 infection both in and outside China,as well as evidence-based medical information,this consensus focuses on the clinical characteristics of severe or critical COVID-19 adults with Omicron subvariant infection,related indicators of disease progression,imaging characteristics,antiviral treatment,respiratory support,anticoagulation and blood purification treatment,Traditional Chinese medicine(TCM)treatment,standards for ICU discharge,etc.,summarizes 10 recommendations.In particular,new insights into the selection and duration of antiretroviral therapy have been provided.

关 键 词：奥密克戎变异株 新型冠状病毒 重症 治疗 专家共识 

分 类 号：R511[医药卫生—内科学]